Recently, in clinical treatment strategies for HCC, sorafenib and Anti-PD-1 immunotherapy has benefited only a fraction of patients.2,3,33 In order to expand the scope of beneficiary patients, we conducted an in-depth analysis of the HCC microenvironment and explored the role of the CCL21/CCR7 axis in different components to accurately guide the precision treatment for HCC. This evidence concerns the gene CCR7 and hepatocellular carcinoma.